- Social:
Pharmaceutical Research and Manufacturers of America
Vice president of policy and research for the Pharmaceutical Research and Manufacturers of America, which represents leading research-based pharmaceutical companies in the US
PROFILE
Lori Reilly
Guest
FROM Lori Reilly
To the Point
The Rising Cost of Fighting Cancer One third of all Americans will get some form of cancer during their lifetimes — and the average cost of drug treatment is $100,000 a year. That's five to 10 times what it was 15 years ago and, for many patients, the cost of survival is bankruptcy. Drug companies insist big money is needed to cover research and development, but doctors, insurance companies and regulators say it's time for a change. Why do Americans have to pay more for cancer drugs than Canadians or Europeans?
To the Point
Expiring Patents, Drug Prices and the Hazy Market for Generics Patents are about to expire on two of the world's best-selling prescription drugs. Prices for cholesterol-fighter Lipitor and the blood-thinner Plavix are likely to drop by 80 percent when they're replaced by generics. But that's not all. The drug industry will be faced with an unprecedented wave of expiring patents in the next few years. What will the expiration of patents on many other drugs mean for Big Pharma? How is the industry fighting back? Will consumers get the benefits they deserve?
Recommended
To the Point
Janesville and the American Dream Janesville, Wisconsin is the hometown of Republican House Speaker Paul Ryan. But he couldn’t prevent the closing of the General Motors factory after 100 years. On this Memorial Day rebroadcast of To the Point, we hear what’s happened to what once was a model of American middle-class unity.
Left, Right & Center
President Trump: US to withdraw from the Paris Climate Accord Trump says he was elected to serve Pittsburgh, not Paris.
To the Point
Replacing Obamacare: Now you see it… now you don’t As the Senate deliberates replacing Obmacare, health coverage for millions of people is at stake. There've been no public hearings, and a draft measure won't be made public. Is the House version so unpopular that that Senate is hiding a version that looks much the same?